AU2021295437A1 - Arimoclomol for treating gaucher disease - Google Patents

Arimoclomol for treating gaucher disease Download PDF

Info

Publication number
AU2021295437A1
AU2021295437A1 AU2021295437A AU2021295437A AU2021295437A1 AU 2021295437 A1 AU2021295437 A1 AU 2021295437A1 AU 2021295437 A AU2021295437 A AU 2021295437A AU 2021295437 A AU2021295437 A AU 2021295437A AU 2021295437 A1 AU2021295437 A1 AU 2021295437A1
Authority
AU
Australia
Prior art keywords
active pharmaceutical
pharmaceutical ingredient
use according
day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021295437A
Other languages
English (en)
Inventor
Cathrine Kolster Fog-Tønnesen
Anders Mørkeberg HINSBY
Linda INGEMANN
Thomas Kirkegaard Jensen
Christine Í DALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zevra Denmark AS
Original Assignee
Zevra Denmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zevra Denmark AS filed Critical Zevra Denmark AS
Publication of AU2021295437A1 publication Critical patent/AU2021295437A1/en
Assigned to Zevra Denmark A/S reassignment Zevra Denmark A/S Request for Assignment Assignors: ORPHAZYME A/S
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021295437A 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease Pending AU2021295437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20182067.7 2020-06-24
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
AU2021295437A1 true AU2021295437A1 (en) 2023-02-02

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021295437A Pending AU2021295437A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Country Status (14)

Country Link
US (1) US20230226036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2023531750A (cg-RX-API-DMAC7.html)
KR (1) KR20230035586A (cg-RX-API-DMAC7.html)
CN (1) CN116075305A (cg-RX-API-DMAC7.html)
AU (1) AU2021295437A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026396A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4171559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056005T3 (cg-RX-API-DMAC7.html)
IL (1) IL299250A (cg-RX-API-DMAC7.html)
MX (1) MX2023000033A (cg-RX-API-DMAC7.html)
PT (1) PT4171559T (cg-RX-API-DMAC7.html)
WO (1) WO2021260120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL299250A (en) 2023-02-01
EP4171559A1 (en) 2023-05-03
BR112022026396A2 (pt) 2023-03-14
KR20230035586A (ko) 2023-03-14
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP7849574B2 (ja) 2026-04-21
JP2026042936A (ja) 2026-03-11
JP2023531750A (ja) 2023-07-25
EP4171559B1 (en) 2025-09-10
ES3056005T3 (en) 2026-02-17
CN116075305A (zh) 2023-05-05
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
US20230226036A1 (en) 2023-07-20
DK4171559T3 (da) 2025-12-15
JP2026104910A (ja) 2026-06-25

Similar Documents

Publication Publication Date Title
US20220226262A1 (en) Methods of treating doose syndrome using fenfluramine
US20040167226A1 (en) Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
Steinberg et al. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
RU2371173C2 (ru) Мемантин для лечения болезни альцгеймера легкой и от легкой до умеренной степени тяжести
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
US10016409B2 (en) Method for improving interstitial flow
US7713984B2 (en) Pharmaceutical uses
CN117177741A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
KR20200121819A (ko) 하지 불안 증후군을 치료하기 위한 치료제
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
JP2016523262A (ja) 慢性外傷性脳障害ｉｉを予防及び／又は治療する方法
HK40090895A (en) Arimoclomol for treating gaucher disease
HK40090895B (en) Arimoclomol for treating gaucher disease
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
WO2017207600A1 (en) New treatment of sma
TW202604498A (zh) 劑量方案
WO2024246686A1 (en) Treatment for amyotrophic lateral sclerosis (als)
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
JP2005538067A (ja) 副鼻腔炎の処置方法
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
HK40083824A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ZEVRA DENMARK A/S

Free format text: FORMER APPLICANT(S): ORPHAZYME A/S